Compare Aurora Cannabis Inc (ACB) vs Revvity Inc (RVTY) Price & Performance

Aurora Cannabis (ACB) trades at $3.79, up 31.14% amid a hostile takeover bid from Curaleaf at $4 per share. The stock shows neutral technical signals with bearish moving averages. Fundamentally, 2025 revenue grew to $343.29M with a slim net profit of $1.59M, but 2026 projections indicate a net loss of $120M. Analyst consensus is mixed with 21.43% buy ratings, reflecting uncertainty over the acquisition offer and standalone prospects.

The outlook hinges on the takeover outcome; acceptance could provide immediate upside, while rejection may pressure shares given weak 2026 forecasts. Key risks include execution challenges, regulatory hurdles, and competitive pressures. Investors face a binary event driving near-term volatility.

RVTY trades at $115.18, down 0.72% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q2 2026 earnings of $1.41 per share, beating estimates, and raised its full-year outlook, driven by diagnostics strength and AI-enabled drug discovery. Revenue for 2025 was $2.86 billion with a net income margin of 8.16%, though valuation ratios like P/E of 55.64 appear elevated. Recent news includes product launches like the SuperFlex prenatal system and presentations at investor conferences.

The outlook is positive with analyst consensus favoring a buy rating and a $120.50 price target, suggesting upside. Key opportunities include robust diagnostics demand and innovation pipelines, while risks involve high valuation multiples and competitive pressures in the healthcare sector. Cash flow improved in 2026 to a net positive $31 million, supporting growth initiatives.